Dr Sergei Yakneen

Sergei Yakneen is the Chief Technology Officer and part of the founding team at Isomorphic Labs, an AI company redefining drug design. With over 20 years of experience in scientific research, engineering, machine learning, and product management focused on healthcare and life science, Sergei leads the company's Engineering, Computational Biology, Product, and Data Strategy functions, as well as overseeing its Lausanne office.  

At Isomorphic Labs, he plays a critical role in advancing the company's mission to solve all disease. In May 2024, Isomorphic Labs alongside Google DeepMind, developed and released AlphaFold 3, a pioneering AI model that predicts the structure and interactions of all life's molecules with unprecedented accuracy. Isomorphic Labs has since built a world-leading AI drug design engine comprising foundational AI models that are capable of working across multiple therapeutic areas and drug modalities. Isomorphic Labs is advancing a broad drug design portfolio through partnered programs and wholly-owned internal programs in multiple therapeutic areas.  

Before joining Isomorphic Labs, Sergei was Senior Vice President and CTO at SOPHiA GENETICS, where he oversaw the development and operation of an AI-based molecular diagnostics and data-driven medicine platform used in over 70 countries. His distinguished earlier career also includes launching the first Canadian software engineering center for Amazon.com, developing a Governance, Risk, and Compliance platform at BPS Inc., and leading the Technical Working Group for the Pan Cancer Analysis of Whole Genomes Project, the world’s largest cancer data analysis initiative at the Ontario Institute for Cancer Research and the European Molecular Biology Laboratory. Sergei holds a PhD in computer science from Heidelberg University, where his doctoral research focused on developing novel distributed algorithms for analysing cancer genomes, and a degree in computer science and mathematics from the University of Toronto.